People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

Cipla is preparing to enter the weight-loss drug making sector, heating the competition with US-based Eli Lilly & Co and ...

Pharmaceutical giant Cipla plans to enter India's weight management sector, while also bolstering its central nervous system ...

Cipla is set to enter India's weight management market, addressing the increasing demand for obesity solutions, while also ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

Sales of anti-obesity drugs like Mounjaro and Wegovy are seeing a jump due to a surge in popularity, Business Standard ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Just two days after Novo Nordisk launched Wegovy (semaglutide 2.4 mg) in India, Eli Lilly received regulatory approval for the KwikPen® format of its rival therapy Mounjaro (tirzepatide) ...

Wegovy, the GLP-1 medication to treat obesity from Lilly competitor Novo Nordisk, will still be covered under plans managed by CVS Caremark, along with a few other medications that are generally ...